Nanosomal tacrolimus - Intas Pharmaceuticals/Jina Pharmaceuticals

Drug Profile

Nanosomal tacrolimus - Intas Pharmaceuticals/Jina Pharmaceuticals

Alternative Names: Nanosomal tacrolimus; Tacrolimus liposomal; Tacrolimus-Lipid Suspension

Latest Information Update: 25 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Class Lactones; Macrolides; Skin disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Transplant rejection
  • Phase III Atopic dermatitis
  • Phase II Lichen planus; Rheumatoid arthritis

Most Recent Events

  • 25 Jun 2018 Launched for Transplant rejection in India (IV) (Intas pharmaceuticals pipeline, before June 2018)
  • 01 Jun 2018 Intas Pharmaceuticals plans a phase III trial for Lichen planus in India (CTRI2018-05-013796)
  • 30 Apr 2018 Intas Pharmaceutical completes a phase III trial in Atopic dermatitis in India (Topical) (CTRI2016-02-006642)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top